Aurora reported a growth in revenue for the quarter, representing a 223 percent improvement over the same time period last year. The cannabis producer generated C$19.1 million in revenue during Q4.
According to the company, this uptick in revenue was due to a “higher average selling price, per gram of dried cannabis, coupled with a higher proportion of cannabis oil sales.”
The company also indicated in its financials that it expects to produce 150,000 kilograms of cannabis per year at the end of Q2 2019, once all of its licensed facilities are at full capacity.
As part of its expansion, the company secured a C$200 million debt facility with the Bank of Montreal (TSE:BMO) in September. At the end of the quarter the producer held an C$89 million cash position.
US listing will offer new investors chance for cannabis exposure
In its report, the company confirmed a premier US exchange listing is coming. Aurora CEO, Terry Booth, said the listing would give access to a “broader investor audience” the opportunity to participate in the company.
The company will file a registration form with the US Securities and Exchange Commission (SEC) and will seek, pending approval, its proper US exchange.
Aurora’s pending US listing will arrive following the company’s decision to spin off a separate entity, Australis Capital (CSE:AUSA), which is set to pursue opportunities in the US multistate operator business model.
Australis made its public debut on the Canadian Securities Exchange (CSE) on September 19. Aurora shareholders obtained a stake in the new venture as part of the launch.
During an investor and analyst conference call on Tuesday (September 25), management of the company was asked whether this upcoming US listing will affect the potential for the company to find an established partner outside of cannabis.
Aurora was at the center of rumors of The Coca-Cola Company (NYSE:KO) potentially entering the cannabis space through a partnership looking to develop infused wellness beverages.
Management of the producer was also asked whether the company is inclined to look for a deal in which it retains control or find a partner to take over.
Booth said while it is exciting to see the entry of large companies with no relation to cannabis, Aurora is not “in the mood to be selling out anytime soon.”
“When you start to see the revenues that this company is going to generate on a global basis, then you will see even more attraction coming from these larger companies,” Booth said.
Cam Battley, chief corporate office for Aurora, added the company is well positioned for a deal but is also holding reservation on the type of deal it makes.
In terms of the US listing moving the needle for a potential deal with an established player, Battley said the new investing option “won’t affect things immediately.” Rather, Battley said, it is seen as a move to allow the entry of more investors.
Stock for Aurora quickly increased in value during Tuesday’s early trading session. The company rose to a share price of C$12.92, indicating a 5.30 percent increase, as of 1:25 p.m. EST.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).